SAGE - Sage Therapeutics Company Aggregate Debts

This chart illustrating the price history of Sage Therapeutics, Inc. (SAGE) debt on the GURU.Markets platform is based on a strategy of outsourcing drug production to external contractors under strict internal supervision. Its first-mover status in depression treatment provides the company with leverage for flexible therapy pricing. The current metric stands at 0.01, while the reduction of R&D expenses supports liquidity despite demand sensitivity.

This indicator aggregates the total volume of confirmed borrowed funds, allowing for an assessment of financial stability and default risk through leverage dynamics. By analyzing the volume of credit obligations, an investor can determine the cost of capital required by Sage Therapeutics, Inc. (SAGE) to finance the costly development of neuroactive steroids and the market launch of breakthrough drugs for the therapy of CNS depressive disorders.